Erythrocytes as carriers for drugs: the transition from the laboratory to the clinic is approaching

Erythrocytes have been suggested to be smart carriers for drugs, biologics and other therapeutic agents, and a paper in the present issue of the journal confirms the wide interest and the expectations the technology has generated. In this Editorial, I briefly summarize the advances in the field and try to figure out the process that will take this technology to the clinic. The conclusion is that, after several years of basic research, the time is fast approaching since two companies in Europe are actively engaged in industrializing the process and searching approval for treatments with structured clinical trials.

[1]  M. Magnani,et al.  Cell-based drug delivery. , 2008, Advanced drug delivery reviews.

[2]  V. Muzykantov,et al.  Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. , 2010, Blood.

[3]  R H Glew,et al.  Enzyme loading of erythrocytes. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Vladimir R Muzykantov,et al.  Drug delivery by red blood cells: vascular carriers designed by mother nature , 2010, Expert opinion on drug delivery.

[5]  Robert Franco,et al.  International seminar on the red blood cells as vehicles for drugs , 2012, Expert opinion on biological therapy.

[6]  Vladimir R Muzykantov,et al.  Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes , 2003, Nature Biotechnology.

[7]  Mauro Magnani,et al.  Drug delivery by red blood cells , 2011, IUBMB life.